An interferon-gamma release assay test performs well in routine screening for tuberculosis

Danish Medical Journal

Volumn 61, Issue 6, 2014, Pages

  Vestergaard Danielsen, Allan ^a   Fløe, Andreas ^a   Lillebaek, Troels ^b   Jürgen Hoffmann, Hans ^a   Hilberg, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; AGED; ARTICLE; ATYPICAL MYCOBACTERIUM; CHILD; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MICROBIOLOGY; MYCOBACTERIUM GORDONII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM PEREGRINUM; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK; SCREENING TEST; SEASON; SEASONAL VARIATION; SENSITIVITY ANALYSIS; TUBERCULOSIS;

EID: 84901593503     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. WHO. Global Tuberculosis Report 2013. Geneva: World Health Organization, 2013.
2. Chee CB, Sester M, Zhang W et al. Diagnosis and treatment of latent infection with mycobacterium tuberculosis. Respirology 2013;18:205-16.
3. Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-73.
4. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferongamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75
5. Pai M, Riley LW, Colford JM, Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76.
6. Erkens CG, Kamphorst M, Abubakar I et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-49.
7. Vassilopoulos D, Tsikrika S, Hatzara C et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting antitumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-8.
8. Beffa P, Zellweger A, Janssens JP et al. Indeterminate test results of T-SPOT. TB performed under routine field conditions. Eur Respir J 2008;31:842-6.
9. Mancuso JD, Tribble D, Mazurek GH et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin Infect Dis 2011;53:234-44.
10. Hinks TS, Varsani N, Godsiff DT et al. High background rates of positive tuberculosis-specific interferon-gamma release assays in a low prevalence region of UK: a surveillance study. BMC Infect Dis 2012;12:339.
11. Ferrara G, Losi M, D'Amico R et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34.
12. Ravn P. Screening for tuberculosis infection prior to medical therapy. Ugeskr Læger 2011;173:893-6.
13. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010;137:952-68.
14. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
15. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41(Suppl 3):S199-S203.
16. Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
17. Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol 2013;9:524-31.
18. Bocchino M, Matarese A, Bellofiore B et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNFalpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-13.
19. Kamper-Jorgensen Z, Andersen AB, Kok-Jensen A et al. Clustered tuberculosis in a low-burden country: nationwide genotyping through 15 years. J Clin Microbiol 2012;50:2660-7.
20. Arend SM, de Haas P, Leyten E et al. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 2005;191:1301-10.